MultiCare Health System

Main Phone Number800-342-9919   Online ChatOnline Chat
Institute for Research & Innovation

Multiple Sclerosis - Neuropathic Pain

Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis

Purpose: This study is seeking patients who have clinically diagnosed MS-related central neuropathic pain, but are otherwise in generally good health.

Who Can Participate?
Patients who have been diagnosed with MS-related central neuropathic pain for at least 90 days prior to study participation. Patient may be on any or no MS modifying therapy.

Diagnosis or Condition
: Patients with a clinical diagnosis of Multiple Sclerosis

: Investigational Product is delivered via oral capsule twice daily.

: Between 18 and 85 years of age

: Males and Females

:  Seven visits over a period of 13 weeks

: You will be compensated for your time and travel

Principal Investigator(s)
John Huddlestone, MD, FAAN

Study Coordinator
:   Andrea Thompson, 253-403-7440